YKYY031 injection for advanced solid tumors with specific genetic mutations
Part of Cancer clinical trials.
This early-stage trial tests a new cancer treatment (YKYY031) given by injection for advanced colorectal or pancreatic cancer that has stopped responding to standard treatments. The drug is designed to target specific genetic changes (mutations) found in some tumors, and your immune system must match a particular genetic marker (HLA-A*11:01) for the drug to work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Advanced or metastatic solid tumor (colorectal or pancreatic cancer) that has failed prior standard treatments
- Tumor carries one of the specific genetic mutations (KRAS, PIK3CA, TP53, BRAF, or FBXW7 changes)
- You have the genetic marker HLA-A*11:01
- Good overall health and organ function (blood counts, liver, kidney, heart)
- At least one measurable tumor on imaging; expected to live at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called YK1101 for people with advanced solid tumors that have not responded to standard treatment. It targets a specific protein (MAGE-A4) on cancer cells and requires a matching genetic type called HLA-A*11:01.
This trial tests a new drug called GK01 in patients with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, and may be an option for those who can have a tumor surgically removed.
This trial tests an injection of your own immune cells (tumor-infiltrating lymphocytes) to see if they can fight advanced solid tumors like stomach or lung cancer. Doctors will remove one of your tumors, grow the immune cells from it, and then give them back to you.
This trial tests an experimental cell treatment called GK01 for people with advanced solid tumors that have stopped responding to standard therapies. The goal is to see if it can help shrink tumors or slow their growth.
This trial tests an experimental injection called GKL-006 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and helps shrink or control the cancer.
This Phase 1 trial tests an engineered immune cell treatment (“T cells”) made to recognize a specific tumor change (KRAS G12V) in people with advanced solid tumors. It’s intended for cancers that did not respond to standard treatments, and the goal is to see safety and early signs of benefit.
Hear when a new Malignant Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.